ST2 is a member of IL-1 receptor family expressed on Th2 cells and regulates Th2 responces. The gene of ST2 encodes soluble ST2 (sST2) and the transmembrane ST2 (ST2L) isoforms through alternative mRNA splicing. The discovery of IL33/ ST2 signaling pathway, has drawn a great scientifi c attention to this system. sST2 has been shown to be an indacating factor in various infl ammatory conditions. This study aims to evaluate serum sST2 levels in HTLV-1 infected patients. This study included 49 HTLV-1 seropositive cases of which 14 were sympthomatic. Controls consisted of 30 healthy volunteers. sST2 level was measured using a quantitative ELISA assay and the results of the study groups were compared. Corroborating the previous reports, sST2 was lower in females (P = 0.003). The sST2 levels was slightly increased in HTLV-1 patients, though such increase was not statistically significant (P = 0.91), in addition sST2 level did not correlate signifi cantly to the disease duration (P = 0.78). Despite some other chronic viral infection, HTLV-1 seems not to induce high serum sST2. However owing to relatively high normal variation of sST2 levels and rather small sample size, we stongly recommend further reseach with preferably larger sample size to evalute sST2 in HTLV-1 infected patients.
Introduction
The human T-lymphotropic virus type 1 (HTLV-1), one of the fi rst known human retroviruses affecting 10 to 20 millions people worldwide. HTLV-1 spreads globally and is endemic in Africa, south America, north east of Iran and in some regions of Japan [1] . In about one person out of 20, symptomatic diseases associated with HTLV-1 occurs; among these diseases, adult T-cell leukemia/ lymphoma (ATLL) and HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP) are clinically more signifi cant [2, 3] . HAM/TSP a spastic paraplegia has been confi rmed to be mainly due to the infl ammatory responses in spinal cord [2] . Cytokines are thought to play an important role in neurodegeneration occurring in spinal cord of HAM/TSP patients [4] . High levels of tumor necrosis factor alfa (TNFα) and a number of cytokines such as interleukine-1 β (IL-1β), IL-1α and IL-6 have been observed in these patients [5] [6] [7] .
ST2, also known as IL-1 R4, is a member of the interleukin-1 receptor (IL-1 R) family. ST2 gene encodes two distinict forms of receptors: a long membrane-anchored form (ST2L), which is expressed on mast cells [8] , macrophages [9] and T helper type 2 but not Th1 cells [10] , and a soluble form (sST2) which is produced through different splicing of the gene [11] .
ST2L which is mainly expressed on activated Th2 cells is thought to mediate Th2 effector functions through IL33/ST2 signalling pathway [10] . IL-33 a cytokine belonging to the IL-1 family which plays a critical role in Th2 immune responses, binds to its receptor ST2L and stimulates the target cells [12, 13] . IL-33 is a multifunctional immunomodulatory cytokine that acts both pro-and anti-infl ammatory depending on the disease state or in vitro experimental conditions [14, 15] . The soluble form of ST2 (sST2) is secreted to the serum and acts as a decoy, negative regulatory receptor, namely binds to the free IL-33 and prevents the IL33/ST2L signaling function. Studies have revealed that stimulation with lipopolysaccharide (LPS), IL-1b, TNF-a and IL-6 induce the production of sST2 [16, 17] . Also, in murine models induction of sST2 expression has been demonstrated by pro-infl ammatory stimuli [9, 18] .
Elevated serum levels of sST2, have been reported in a wide range of diseases such as autoimmune diseases [19] , asthma [20] , sepsis and LPS induced infl ammations [21] , as well as chronic viral infections such as HIV-1 [22] . We hypothesized that due to the Th2 responses during HTLV-1 infection [23] , the sST2 might serve as a marker of progression and severity of the disease in particular in HAM/TSP patients, therefore the sST2 levels in HTLV-1 positive individuals including HAM/TSP patients were studied and compared with healthy controls.
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Methods
Study groups
A total of 49 HTLV-1 positive cases and 30 healthy individuals participated the study. The mean age±SD and gender distribution of different groups are shown in Table I . All HTLV-1 positive patients were diagnosed by HTLV-1 antibody ELISA test and were confi rmed with western blot analysis. The general characteristics of the patients are described in Table II . The control group included 30 healthy blood donors. Controls were confi rmed to be seronegative for HTLV-1, HIV and viral Hepatitis. In addition, they fi lled a questionnaire to reveal any diagnosed infl amatory or other potentially effi cacious pathologic condition. Healthy and carrier samples were prepared in Blood Transfusion Organization of Mashhad. Patient samples were obtained from HTLV-1 clinic of neurology department at Ghaem university hospital in Mashhad. Written informed consent from all participants was obtained.
ST2 measurement
sST2 was measured with Quantikine Human ELISA kit (R&D Systems) according to manufacturer's instructions. This assay employs the quantitative sandwich enzyme immunoassay technique. Samples were diluted 20-fold for assay and the optical density was measured at 450 nm.
Statistical analysis
Statistical analysis was performed with SPSS11.5 software. Each result was expressed as mean and standard deviation. Normal distribution of variable was assessed by Kolmogorov-Smirnov test. Independent samples t-test and ANOVA were used and a two-tailed P value of <0.05 was considered statistically significant in all calculations.
Ethical approval
All samples were collected in accordance with the Helsinki declaration on human research. The study was reviewed and approved by the ethic committee in vice president of research of Mashhad University of Medical Science (MUMS), Mashhad, Iran.
Results
The mean age and gender distribution of healthy controls and HTLV-1 seropositive group were matched and no signifi cant difference was observed (p = 0.84 and 0.06, respectively). Kolmogorov-Smirnov test showed that sST2 distri-bution is normal in control, carrier and symptomatic study groups (p = 0.289, 0.872, 0.995, respectively). Table III shows the mean ± SD of sST2 in different study groups. Statistically no signifi cant diffrence between sST2 levels of controls, carriers and HAM/TSP patients was observed (Anova test, p = 0.384). Moreover, as shown in Figure 1 although an slightly increased sST2 levels in sreopositive groups was observed comparing to healthy controls, such sST2 elevation did not cause signifi cant difference between these groups (t-test, p = 0.91).
We also observed lower levels of serum sST2 in healthy females compared to males (t-test, p = 0.02) a fi nding consisting with previous reports [24, 25] . Similarly, a signifi cant difference between the two genders in seropositive carrier group was observed (t-test, p = 0.006). Such difference was also observed when total female measurements were compared to total male values (t-test, p = 0.003).
To exclude the factor of gender, ST2 levels of control and seropositive group were compared in each sex. As shown in Figure 1 , increased values were observed in male seropositive cases compared to healthy men, although the difference was not statistically signifi cant (t-test, p = 0.52), a similar fi nding was observed in females (t-test, p = 0.11). The serum sST2 levels in asymptomatic carriers were comparable with those in symptomatic HAM/TSP patients. Likewise, serum level of ST2 in HAM/TSP patients did not show any relation with the duration of symptoms (p = 0.565).
Discussion
In this study we investigated sST2 levels in HTLV-1 infected individuals, the study was performed in north east of Iran where HTLV-1 is endemic [26, 27] . The fi ndings showed an increase trend in chronic HTLV-1 infected individuals compared to healthy controls although the difference was not statistically significant. Still the results should be treated and interperated with caution. Given the high normal variation of sST2 levels in the serum a larger sample size might reveal a signifi cant difference.
The participants of the present study had no history of other known infl amatory conditions or cardiac diseases [28] which might affect their sST2 levels. Previous studies indicate that sST2 level is not signifi cantly infl uenced by age [24] , nevertheless in our study the groups were matched according to their age. On the other hand, gender has a signifi cant effect on serum sST2 levels. Different studies have generally report lower sST2 levels in females [24] . Concerning the effect of gender, various groups were compared on the basis of sex to control this confounding factor, yet, no signifi cant differences were observed.
As mentioned before, high levels of a number of cytokines have been observed in HAM/TSP patients [5] [6] [7] . Therefore it seems reasonable to assume that other kinds of cytokines might also contribute in the development of HAM/TSP. In the present study we underscored sST2 production during HTLV-1 infection. However the presented data should be treated as an original idea to propose upcoming studies.
There are several limitations to our study. First, it is limited by a relatively small number of patients. We did not simultaneously measure levels of IL-33 and thus cannot comment on the IL-33/sST2 ratio, which might offer additional mechanistic insights. The other important limitation of the study, like many other patient-based studies is lack of information on some potential confounding factors. However, we considered some major confounders and addressed them by a researcher-made questionarie, and it is unlikely that confounding from minor remained underlying factors have greatly affected the results.
To conclude within our study groups, sST2 levels were slightly higher in infected individuals, although such preliminary interpretation merits further confi rmatory studies with preferably a higher sample size to assess the pathologic role and clinical relevance of sST2. Such studies should be particularly designed in accordance with disease progression to assess any potential predictive value of sST2 for development of HTLV-1 associated myelopathy.
